Legend Biotech (NASDAQ: LEGN) announced on May 4, 2026, the engagement of six distinguished scientific advisors:
Renier Brentjens, Spencer Fisk, Carl June, Maximilian F. Konig, Anthony Polverino, and Georg Schett.
The advisors provide expertise in oncology, immunology, development, and cell therapy manufacturing to guide translational research, clinical development, and manufacturing strategy.
Their role is to offer strategic input on emerging science, identify unmet medical needs, and support Legend's evolution toward a diversified next-generation cell therapy pipeline.
CEO Ying Huang stated that the advisors' experience will help shape long-term scientific direction and innovation beyond the current portfolio.
The announcement focuses on scientific guidance with no new funding, deals, or partnerships disclosed.